Rigel Pharmaceuticals (NASDAQ:RIGL)’s traded shares stood at 0.67 million during the last session, with the company’s beta value hitting 1.27. At the close of trading, the stock’s price was $20.20, to imply a decrease of -0.83% or -$0.17 in intraday trading. The RIGL share’s 52-week high remains $29.82, putting it -47.62% down since that peak but still an impressive 62.97% since price per share fell to its 52-week low of $7.48. The company has a valuation of $360.83M, with an average of 0.25 million shares in intraday trading volume over the past 10 days and average of 269.93K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Rigel Pharmaceuticals (RIGL), translating to a mean rating of 2.20. Of 5 analyst(s) looking at the stock, 0 analyst(s) give RIGL a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.09.
Rigel Pharmaceuticals (NASDAQ:RIGL) trade information
After registering a -0.83% downside in the last session, Rigel Pharmaceuticals (RIGL) has traded red over the past five days. The 5-day price performance for the stock is 0.35%, and -3.02% over 30 days. With these gigs, the year-to-date price performance is 20.10%. Short interest in Rigel Pharmaceuticals (NASDAQ:RIGL) saw shorts transact 1.48 million shares and set a 6.4 days time to cover.
The extremes give us $1 and $2 for target low and target high price respectively. As such, RIGL has been trading 90.1% off suggested target high and 95.05% from its likely low.
Rigel Pharmaceuticals (RIGL) estimates and forecasts
The rating firms project that company’s revenue will grow 10.32% compared to the previous financial year.
Revenue forecast for the current quarter as set by 5 analysts is 43.87M. Meanwhile, for the current quarter, a total of 4 analyst(s) estimate revenue growth to 48.32M.Earnings reports from the last fiscal year show that sales brought in 29.53M and 36.84M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 48.56% before jumping 31.15% in the following quarter.
RIGL Dividends
Rigel Pharmaceuticals has its next earnings report out on 2025-Mar-03. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Rigel Pharmaceuticals (NASDAQ:RIGL)’s Major holders
Rigel Pharmaceuticals insiders hold 2.84% of total outstanding shares, with institutional holders owning 68.53% of the shares at 70.53% float percentage. In total, 68.53% institutions holds shares in the company, led by ARMISTICE CAPITAL, LLC. As of 2024-06-30, the company held over 1.62 million shares (or 9.2541% of shares), all amounting to roughly $13.35 million.
The next major institution holding the largest number of shares is MORGAN STANLEY with 1.42 million shares, or about 8.1193% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $11.71 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Rigel Pharmaceuticals (RIGL) shares. Going by data provided on Dec 31, 2024 , Vanguard Total Stock Market Index Fund holds roughly 548.78 shares. This is just over 3.07% of the total shares, with a market valuation of $11.09 million. Data from the same date shows that the other fund manager holds a little less at 485.49, or 2.72% of the shares, all valued at about 9.81 million.
